Detecting the TNF-α -308G/A Polymorphism by Quantitative PCR and its Correlation with Therapeutic Efficacy in Ankylosing Spondylitis.

What was studied

This study tested a lab method for finding a gene variant called TNF-α -308G/A. The method is a fluorescent PCR test that uses a probe. The team checked its accuracy, precision, and stability. A multicentre trial tested the system in 1,045 patients with immune diseases. A last part looked at 32 patients with ankylosing spondylitis who took TNF-α inhibitors.

What they found

The test gave the same result as Sanger sequencing in every sample. Interfering substances did not affect the system. Some patients with the GA genotype had no response to TNF-α inhibitors. All patients with the GG genotype had better results with these drugs.

What it means for patients

The authors say the test proved highly reliable. They say the variant may be a marker that predicts how well TNF-α inhibitors work. This applies to patients with ankylosing spondylitis.

Why it is not certain yet

Only 32 patients with ankylosing spondylitis were in the drug-response part. The abstract describes only a few patients with the GA genotype. The abstract does not say how drug response was measured. The results show a link, not proof of cause.

Source

Detecting the TNF-α -308G/A Polymorphism by Quantitative PCR and its Correlation with Therapeutic Efficacy in Ankylosing Spondylitis.

We restate facts from the source record in our own words. The original wording belongs to its publisher.